Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Genprex Inc (NQ: GNPX )

2.200 USD -0.090 (-3.93%)
Streaming Delayed Price Updated: 11:54 AM EDT, Oct 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 476,611
Open 2.290
Bid (Size) 2.190 (10)
Ask (Size) 2.210 (6)
Prev. Close 2.290
Today's Range 2.150 - 2.300
52wk Range 2.240 - 7.720
Shares Outstanding 47,527,857
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Genprex Strengthens Management Team with Appointments of Industry Leaders Mark S. Berger, M.D. as Chief Medical Officer and Hemant Kumar, Ph.D. as Chief Manufacturing and Technology Officer
Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced... 
From Business Wire News Releases
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Strengthens Management Team with Strategic Appointments
From InvestorBrandNetwork

Performance

YTD
-46.73%
-46.73%
1 Month
-21.15%
-21.15%
3 Month
-27.15%
-27.15%
6 Month
-44.30%
-44.30%
1 Year
-32.72%
-32.72%

More News

Read More
Genprex to Participate in September Investor Conferences
From Business Wire News Releases
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation in Two Upcoming Investor Conferences
From InvestorBrandNetwork
Genprex to Participate in a Monthly CEO Roadshow Webinar Series
From Business Wire News Releases
InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Participate in CEO Roadshow Webinar Series
From InvestorBrandNetwork
12 Health Care Stocks Moving In Wednesday's After-Market Session
Tags OTRKP ADMA GBS
From Benzinga
Genprex Announces Initiation of its Phase 1/2 Acclaim-1 Clinical Trial for REQORSA™ Immunogene Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer Following FDA Review
From Business Wire News Releases
12 Health Care Stocks Moving In Thursday's After-Market Session
Tags ARPO BZI/TFM NVIV
From Benzinga
Analysts Predict 25% Gains Ahead For The Holdings of FDM
Tags ETFs
From ETF Channel
Genprex Announces Participation in Noble Capital Markets’ Virtual Roadshow Series
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.